[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"interstitial-lung-disease-due-to-connective-tissue-disease-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:interstitial-lung-disease-due-to-connective-tissue-disease-disorder":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,67,95,126],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":66},"100630072","optimizing-the-diagnostic-journey-in-interstitial-lung-disease-the-optimize-ild-1-trial-100630072",false,"NCT07482917","Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 Trial","OPTIMIZE-ILD-1: A Randomized, Pragmatic, Parallel-Group Trial Evaluating the Impact of an Optimized Diagnostic Circuit on Time to Diagnosis in Patients With Suspected Interstitial Lung Disease","OPTIMIZE-ILD-1","Inclusion Criteria:\n\n* Age 18 years or older.\n* Referral for suspected or undiagnosed interstitial lung disease (ILD).\n* At least one of the following:\n\n  * A finding suggestive of ILD (such as reticulation, ground-glass opacities, traction bronchiectasis or honeycombing) not attributable to another disease, on a CT available at referral that includes the lung parenchyma, regardless of its indication; or\n  * Persistent or progressive shortness of breath or chronic cough not attributable to another disease, accompanied by at least one of the following: an interstitial or reticular pattern on chest radiograph; reduced forced vital capacity; persistent bibasilar crackles or digital clubbing; a relevant environmental or occupational exposure, autoimmune disease, or suspected drug or radiation toxicity; or a first-degree family history of ILD.\n* Ability to provide informed consent.\n\nExclusion Criteria:\n\n* Complete ILD diagnostic work-up already performed (chest CT plus full pulmonary function testing including six-minute walk test plus complete ILD laboratory panel).\n* Established diagnosis of ILD previously assigned by another center or specialist.\n* Clinical instability or acute illness that would prevent reliable completion of diagnostic procedures (e.g., respiratory infection, suspected acute ILD exacerbation, acute heart failure).\n* Acute iatrogenic pneumonitis (drug-, chemotherapy- or radiation-induced) with a clear temporal relationship to the offending agent.\n* Medical, functional, psychiatric or logistical limitations that, in the investigators' opinion, would interfere with the diagnostic process or data collection.\n* Participation in another interventional clinical trial that may alter the frequency or timing of diagnostic procedures.\n* Cognitive impairment that prevents informed consent or completion of study questionnaires.\n* Refusal to participate or to allow the collection or use of clinical data.","ALL","18 Years",{"count":20,"type":21},92,"ESTIMATED","INTERVENTIONAL",[24],"NA","The OPTIMIZE-ILD-1 trial is a prospective, randomized, open-label clinical trial designed to evaluate the impact of a coordinated diagnostic pathway on patients with suspected interstitial lung disease (ILD). In routine clinical practice, diagnostic workflows for ILD are frequently fragmented, involving multiple independent appointments that can lead to significant delays and increased burden for patients and caregivers. This study compares the standard diagnostic pathway against an optimized circuit where core diagnostic procedures-such as high-resolution CT, pulmonary function tests, and laboratory panels-are pre-bundled and scheduled within a coordinated and compressed timeframe.\n\nAll eligible patients referred for suspected ILD are included consecutively to ensure a pragmatic, real-world representation of the referral population. The primary objective is to measure the time to diagnostic communication, defined as the duration from randomization to the date the patient is formally informed of the final diagnosis following a multidisciplinary team (MDT) consensus. Secondary objectives include assessing the time to MDT diagnosis, the time to treatment initiation (when clinically indicated), socioeconomic cost-burden, and the environmental carbon footprint of the diagnostic journey. Furthermore, the study evaluates health-related quality of life, psychological distress, and clinical frailty, while exploring factors such as language proficiency as determinants of diagnostic equity. Caregiver-related outcomes, including burden and experience measures, are contingent upon the presence of a primary caregiver and the provision of their independent informed consent.\n\nThe design of this protocol was informed by a patient focus group and is officially endorsed by the 'AIRE' Associació Catalana de Malalts i Trasplantats Pulmonars, ensuring a patient-centered approach that prioritizes the diagnostic journey's efficiency and human impact.",[27,28,29,30,31],"Interstitial Lung Disease (ILD)","Suspected Interstitial Lung Disease","Fibrotic Interstitial Lung Disease","Idiopathic Pulmonary Fibrosis (IPF)","Interstitial Lung Disease Due to Connective Tissue Disease (Disorder)",[33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53],"Interstitial Lung Disease","ILD","Suspected ILD","Pulmonary Fibrosis","Idiopathic Pulmonary Fibrosis","Connective Tissue Disease-ILD","IPF","Diagnostic Pathway","Diagnostic Delay","Multidisciplinary Discussion","One-Day ILD Clinic","Time to Diagnosis","Time to Treatment Initiation","Organizational Intervention","Health Services Research","Diagnostic Workflow Optimization","Patient Experience","Quality of Life","Pulmonary Function Tests","High-Resolution CT","Carbon Footprint","RECRUITING","2026-06-30",{"date":57,"type":58},"2026-07-02","ACTUAL",{"date":60,"type":58},"2026-03-09",{"date":62,"type":21},"2028-03-01",{"name":64,"class":65},"Hospital de Granollers","OTHER",1,{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":22,"phases":76,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":66},"100630376","phase-2-emapalumab-mda5-rapidly-progressive-interstitial-lung-disease-rp-ild-study-100630376","NCT07486869","Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study","Emapalumab for the Treatment of Anti-MDA5 Antibody Positive Rapidly Progressive Interstitial Lung Disease","Inclusion Criteria:\n\n* Progressive interstitial lung disease as determined by at least 2\u002F4 of the following:\n\n  1. worsening respiratory symptoms;\n  2. worsening or new oxygen requirement;\n  3. worsening disease on CT chest;\n  4. worsening Forced Vital Capacity (FVC1) or Diffusing Capacity for Carbon Monoxide (DLCO) on pulmonary function tests\n* MDA5 antibodies present\n* Elevated ferritin above the upper limit of normal (ULN)\n* Participant at least 18 years old\n\nExclusion Criteria:\n\n* Active, untreated bacterial, mycobacterial or fungal infection\n* Active herpes zoster infection\n* Currently requiring extracorporeal membrane oxygenation (ECMO)\n* Participant refusal to participate in the study\n* Pregnant women\n* Prisoners",{"count":75,"type":21},5,[77],"PHASE2","This is a proof of concept study to determine if Emapalumab appears effective for the treatment of anti-MDA5 antibody positive rapidly progressive interstitial lung disease (MDA5 RP-ILD). Emapalumab is a medication that is currently used for a severe problem with the immune system, called macrophage activation syndrome, and this disease shares some similar features with MDA5 RP-ILD.",[80,81,82,83,84,33,31],"Dermatomyositis","Dermatomyositis Sine Myositis","Dermatomyositis With Myopathy","Dermatomyositis With Respiratory Involvement","Dermatomyositis With Organ Involvement","NOT_YET_RECRUITING","2026-06-16",{"date":88,"type":58},"2026-06-18",{"date":90,"type":21},"2026-07",{"date":92,"type":21},"2027-05",{"name":94,"class":65},"University of Miami",{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":22,"phases":105,"briefSummary":106,"conditions":107,"keywords":109,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":124,"leadSponsor":125,"locationsCount":66},"100630325","optimizing-the-follow-up-journey-in-interstitial-lung-disease-the-optimize-ild-2-trial-100630325","NCT07486206","Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 Trial","OPTIMIZE-ILD-2: A Randomized, Pragmatic, Parallel-Group Trial Evaluating the Impact of an Optimized Coordinated Follow-Up Circuit on Time Burden in Patients With Interstitial Lung Disease","OPTIMIZE-ILD-2","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Established diagnosis of interstitial lung disease (ILD).\n* Currently receiving antifibrotic therapy, immunosuppressive therapy, or both, as part of routine ILD care.\n* Under active follow-up at the participating ILD center.\n* Able to attend the required follow-up procedures included in the study visit.\n* Able to provide informed consent.\n\nExclusion Criteria:\n\n* Inability to complete the coordinated follow-up visit for non-medical reasons (e.g., logistical impossibility).\n* Clinical instability or acute illness interfering with planned follow-up procedures (such as respiratory infection, suspected ILD exacerbation, acute heart failure, or other acute conditions).\n* Participation in another interventional clinical trial that may alter visit frequency or follow-up structure.\n* Cognitive impairment preventing informed consent or completion of questionnaires.\n* Patient refusal to participate or refusal to allow data collection.",{"count":104,"type":21},152,[24],"The OPTIMIZE-ILD-2 trial is a prospective, randomized, open-label clinical trial designed to evaluate the impact of a coordinated follow-up pathway on patients with established interstitial lung disease (ILD). In routine clinical practice, follow-up workflows for ILD are frequently fragmented, requiring multiple hospital visits for pulmonary function tests, laboratory analysis, treatment administration, and consultations with various specialists, which increases the burden for both patients and caregivers. This study compares the standard follow-up care against an optimized circuit where all routine monitoring procedures and interdisciplinary consultations are pre-bundled and scheduled within a single, coordinated hospital visit.\n\nAll eligible patients under active ILD follow-up are included consecutively to ensure a pragmatic, real-world representation of the treated ILD population. The primary objective is to measure the total follow-up time burden, defined as the total home-to-home time required to complete the follow-up circuit. As a cross-sectional assessment within a longitudinal context, secondary objectives include assessing socioeconomic cost-burden, the environmental carbon footprint of the follow-up journey, health-related quality of life, and clinical frailty. Caregiver-related outcomes, including burden and experience measures, are contingent upon the presence of a primary caregiver and the provision of their independent informed consent.\n\nThe design of this protocol was informed by a patient focus group and is officially endorsed by the 'AIRE' Associació Catalana de Malalts i Trasplantats Pulmonars, ensuring a patient-centered approach that prioritizes follow-up efficiency and human impact.",[27,29,30,108,31],"Progressive Pulmonary Fibrosis",[33,34,36,37,108,110,111,112,113,114,115,116,117,43,47,118,46,51,50,49,53,119],"CTD-ILD","Fibrotic ILD","Antifibrotic Therapy","Immunosuppressive Therapy","Follow-Up Pathway","Follow-Up Care Coordination","Time Burden","Home-to-Home Time Burden","Patient-Centered Follow-Up","Multidisciplinary Care","2026-04-06",{"date":122,"type":58},"2026-04-09",{"date":60,"type":58},{"date":62,"type":21},{"name":64,"class":65},{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":22,"phases":135,"briefSummary":136,"conditions":137,"keywords":144,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":158},"100617831","phase-2-a-study-of-bio-300-and-thoracic-radiation-therapy-in-people-with-non-small-cell-lung-cancer-and-interstitial-lung-disease-100617831","NCT07323732","A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease","A Phase II Study of BIO 300 to Reduce the Toxicity of Thoracic Radiotherapy for Patients With Early-Stage Non-Small Cell Lung Cancer and Interstitial Lung Disease (BREATHE)","Inclusion Criteria:\n\n* Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. - Patient age ≥ 18 at time of consent\n* Stage I - II NSCLC (as per the American Joint Commission on Cancer (AJCC) 8th edition)\n\n  ° Pathologically proven diagnosis of cancer is strongly recommended but is not required if the risk of biopsy is unacceptable. If pathological evidence is not available, there must be clinical evidence for NSCLC and multidisciplinary consensus for treatment.\n* Interstitial Lung Disease diagnosis (one of the below)\n\n  * ILD as diagnosed and managed by a pulmonologist\n  * ILD based on diagnostic imaging criteria and abnormal DLCO\n  * ILD as a result of connective tissue diseases (e.g., polymyositis\u002Fdermatomyositis, rheumatoid arthritis, systemic lupus erythematosus, Sjogren's syndrome, scleroderma, mixed connective tissue disease)\n* ECOG performance status of 0 - 3\n* Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrhoeic for 12 months without an alternative medical cause. The following age-specific requirements apply:\n\n  * Women \\\u003C50 years of age would be considered post-menopausal if they have been amenorrhoeic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy).\n  * Women ≥50 years of age would be considered post-menopausal if they have been amenorrhoeic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses \\>1 year ago, had chemotherapy-induced menopause with last menses \\>1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).\n* Life expectancy of at least 6 months\n\nExclusion Criteria:\n\n* Previous thoracic radiation\n* History of pneumonectomy\n* Major surgical procedure (e.g. intra-cranial, intra-thoracic, intra-abdominal, or intra-pelvic) within 28 days prior to enrollment.\n* Severe concurrent illness that may preclude timely completion of thoracic radiation or study procedures\n* Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.\n* ILD exacerbation requiring hospitalization in the last 30 days\n* Poorly controlled cardiac arrhythmias not responding to medical therapy or a pacemaker\n* Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential unless they are willing to employ a highly effective non-estrogen based contraception from screening to 30 days after the last dose of BIO 300 or to abstain from sexual intercourse during these time periods.\n\n  1. Effective method of non-estrogen-based contraception: condom and a diaphragm, condom and intrauterine device, condom and Depo-Provera, condom and Nexplanon, or condom and progesterone mini-pill\n  2. Women who have been off estrogen contraceptives for a minimum 5 days prior to the first scheduled day of study intervention dosing are eligible.\n* Concomitant medications:\n\n  1. Any investigational anticancer therapy.\n  2. Planned concurrent chemotherapy or immunotherapy\n  3. Biologic drugs targeting the immune system (e.g. TNFα blockers, anakinra, rituximab, abatacept, tocilizumab) planned to be use concurrently with BIO 300",{"count":134,"type":21},25,[77],"The purpose of this study to find out whether giving BIO 300 in combination with thoracic radiation therapy is effective in preventing pneumonitis in people with non-small cell lung cancer (NSCLC) and interstitial lung disease (ILD).",[138,139,140,141,142,143,33,31],"NSCLC","NSCLC, Stage I","NSCLC Stage II","Non Small Cell Lung Cancer","Non-small Cell Lung Cancer Stage I","Non-small Cell Lung Cancer Stage II",[141,145,146,138,147,140,33,31,148,149],"Non Small Cell Lung Cancer Stage I","Non Small Cell Lung Cancer Stage II","NSCLC Stage I","Memorial Sloan Kettering Cancer Center","25-310","2026-03-02",{"date":152,"type":58},"2026-03-03",{"date":154,"type":58},"2026-01-06",{"date":156,"type":21},"2029-01-06",{"name":148,"class":65},7]